Mining for the data about glycosylation in the bovines-the analysis of the recently published studies

potential for improvement regarding reproduction, herd health management, and the quality and safety of milk and meat products. The PubMed database was searched for “glycosylation” and “B. taurus” using the following filters: full text available, the publication date of five years, and the preprints excluded. The search retrieved 244 results, and after the content analysis by the authors, 88 remained relevant. All publications were Research Articles except one Review. The assessment of the glycan profile composition was among the aims in 34, the functional aspects in 33, and the protein glycoforms in 12 studies. Ten studies brought data about the total glycome profile of the milk, tissue, or meat sample, while the other contained glycosylation-related features of the individual protein(s). Most often, the studies used milk (25), individual proteins (23), or tissue (20 studies) as the samples. Usually, the milk was material to analyze the glycosylation of casein, immunoglobulin G, or the total glycans. The studies involving the individual proteins most frequently analyzed fetuin, and the glycosylation of submaxillary gland mucin was the target in the studies using tissue samples. These pioneer data mining results allow for the conclusion on the availability of reliable data about glycosylation in the bovines, eligible as the starting point for further scientific efforts on their continuous appending, systematization, and multidisciplinary analyses.Book of abstract: 4th Belgrade Bioinformatics Conference, June 19-23, 202

GLIKOZILACIJA IMUNOGLOBULINA G U BOLESTI COVID-19

The ongoing pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become one of the major health problems in the world. SARS-CoV-2 infection leads to a disease caused by coronavirus (COVID-19), with a spectrum of symptoms ranging from asymptomatic to life-threatening pneumonia and death. A variation in the severity of disease symptomsis one of the central questions in COVID-19 pandemics. Immunoglobulin G (IgG), the most abundant glycoprotein in human blood plasma, is one of the key molecules in immune response. Glycosylation of IgG has been poorly studied in COVID-19, but previous studies on a small sample size have shown that there is an association between glycosylation of IgG and COVID-19 severity. As a part of this doctoral thesis study, the variability of IgG N-glycome in COVID-19 will be extensively studied for the first time, in relation to the disease severity and time period after diagnosis.Pandemija koronavirusa 2 (severe acute respiratory syndrome coronavirus 2, SARS-CoV-2) koji izaziva teški akutni respiratorni sindrom postala je jedan od glavnih zdravstvenih problema u svijetu. Infekcija SARS-CoV-2 dovodi do bolesti uzrokovane koronavirusom (COVID-19) sa spektrom simptoma koji se kreću od asimptomatske bolesti do po život opasne upale pluća i smrti. Uzroci razlika u jačini simptoma kod zaraženih jedno je od glavnih pitanja u pandemiji COVID-19. Imunoglobulin G (IgG), najzastupljeniji glikoprotein u ljudskoj krvnoj plazmi, jedna je od ključnih molekula u imunosnom odgovoru. Unatoč tome, glikozilacija IgG-a je do sada slabo proučavana u bolesnika s COVID-19, a dosadašnje studije na malom broju uzoraka su pokazale da postoji povezanost glikozilacije IgG-a i težine bolesti COVID-19. U sklopu ovog doktorskog istraživanja prvi put će biti detaljno analizirana varijabilnost IgG N-glikoma u COVID-19, ovisno o jačini simptoma te vremenu trajanja bolesti

GLIKOZILACIJA IMUNOGLOBULINA G U BOLESTI COVID-19

The ongoing pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become one of the major health problems in the world. SARS-CoV-2 infection leads to a disease caused by coronavirus (COVID-19), with a spectrum of symptoms ranging from asymptomatic to life-threatening pneumonia and death. A variation in the severity of disease symptomsis one of the central questions in COVID-19 pandemics. Immunoglobulin G (IgG), the most abundant glycoprotein in human blood plasma, is one of the key molecules in immune response. Glycosylation of IgG has been poorly studied in COVID-19, but previous studies on a small sample size have shown that there is an association between glycosylation of IgG and COVID-19 severity. As a part of this doctoral thesis study, the variability of IgG N-glycome in COVID-19 will be extensively studied for the first time, in relation to the disease severity and time period after diagnosis.Pandemija koronavirusa 2 (severe acute respiratory syndrome coronavirus 2, SARS-CoV-2) koji izaziva teški akutni respiratorni sindrom postala je jedan od glavnih zdravstvenih problema u svijetu. Infekcija SARS-CoV-2 dovodi do bolesti uzrokovane koronavirusom (COVID-19) sa spektrom simptoma koji se kreću od asimptomatske bolesti do po život opasne upale pluća i smrti. Uzroci razlika u jačini simptoma kod zaraženih jedno je od glavnih pitanja u pandemiji COVID-19. Imunoglobulin G (IgG), najzastupljeniji glikoprotein u ljudskoj krvnoj plazmi, jedna je od ključnih molekula u imunosnom odgovoru. Unatoč tome, glikozilacija IgG-a je do sada slabo proučavana u bolesnika s COVID-19, a dosadašnje studije na malom broju uzoraka su pokazale da postoji povezanost glikozilacije IgG-a i težine bolesti COVID-19. U sklopu ovog doktorskog istraživanja prvi put će biti detaljno analizirana varijabilnost IgG N-glikoma u COVID-19, ovisno o jačini simptoma te vremenu trajanja bolesti

GLIKOZILACIJA IMUNOGLOBULINA G U BOLESTI COVID-19

The ongoing pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become one of the major health problems in the world. SARS-CoV-2 infection leads to a disease caused by coronavirus (COVID-19), with a spectrum of symptoms ranging from asymptomatic to life-threatening pneumonia and death. A variation in the severity of disease symptomsis one of the central questions in COVID-19 pandemics. Immunoglobulin G (IgG), the most abundant glycoprotein in human blood plasma, is one of the key molecules in immune response. Glycosylation of IgG has been poorly studied in COVID-19, but previous studies on a small sample size have shown that there is an association between glycosylation of IgG and COVID-19 severity. As a part of this doctoral thesis study, the variability of IgG N-glycome in COVID-19 will be extensively studied for the first time, in relation to the disease severity and time period after diagnosis.Pandemija koronavirusa 2 (severe acute respiratory syndrome coronavirus 2, SARS-CoV-2) koji izaziva teški akutni respiratorni sindrom postala je jedan od glavnih zdravstvenih problema u svijetu. Infekcija SARS-CoV-2 dovodi do bolesti uzrokovane koronavirusom (COVID-19) sa spektrom simptoma koji se kreću od asimptomatske bolesti do po život opasne upale pluća i smrti. Uzroci razlika u jačini simptoma kod zaraženih jedno je od glavnih pitanja u pandemiji COVID-19. Imunoglobulin G (IgG), najzastupljeniji glikoprotein u ljudskoj krvnoj plazmi, jedna je od ključnih molekula u imunosnom odgovoru. Unatoč tome, glikozilacija IgG-a je do sada slabo proučavana u bolesnika s COVID-19, a dosadašnje studije na malom broju uzoraka su pokazale da postoji povezanost glikozilacije IgG-a i težine bolesti COVID-19. U sklopu ovog doktorskog istraživanja prvi put će biti detaljno analizirana varijabilnost IgG N-glikoma u COVID-19, ovisno o jačini simptoma te vremenu trajanja bolesti

Genetic architecture of glycomic and lipidomic phenotypes in isolated populations

This dataset contains the extended supplementary tables from the PhD thesis entitled "Genetic architecture of glycomic and lipidomic phenotypes in isolated populations" by Arianna Landini. Understanding how genetics contributes to the variation of complex traits and diseases is one of the key objectives of current medical studies. To date, a large portion of this genetic variation still needs to be identified, especially considering the contribution of low-frequency and rare variants. Omics data, such as proteomics and metabolomics, are extensively employed in genetic association studies as ‘proxies’ for traits or diseases of interest. They are regarded as “intermediate” traits: measurable manifestations of more complex phenotypes (e.g., cholesterol levels for cardiovascular diseases), often more strongly associated with genetic variation and having a clearer functional link than the endpoint or disease of interest. Accordingly, the genetics of omics have the potential to offer insights into relevant biological mechanisms and pathways and point to new drug targets or diagnostic biomarkers. The main goal of the related research is to expand the current knowledge about the genetic architecture of protein glycomics and bile acid lipidomics, two under-studied omic traits, but which are involved in several common diseases. In summary, in my thesis I describe the genetic architecture of the protein glycome and the bile acid lipidome: the former has a higher genetic component, while the latter is largely influenced by environmental factors (e.g., sex, diet, gut flora). Despite the limited sample size, we were able to describe rare variant associations, demonstrating that isolated populations represent a useful strategy to increase statistical power. However, additional statistical power is needed to identify the possible effect of protein glycome and bile acid lipidome on complex disease. A clearer understanding of the genetic architecture of omics traits is crucial to develop informed disease screening tests, to improve disease diagnosis and prognosis, and finally to design innovative and more customised treatment strategies to enhance human health